Peg, VicenteLópez García, María ÁngelesComerma, LauraPeiró, GloriaGarcía-Caballero Parada, TomásConcha López, ÁngelSuárez Gauthier, AnaRuiz, IruneRojo, Federico2021-03-182021-03-182021Future Oncology 2021 17:10, 1209-1218. https://doi.org/10.2217/fon-2020-11001479-6694http://hdl.handle.net/10347/24826Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. TNBC is characterized by increased expression of Programmed Death-ligand 1 (PD-L1), a signal used by many tumors to escape the immune response. Expression of PD-L1 is a positive predictor of response to immunotherapy; therefore, it should be investigated in TNBC in order to select patients who may benefit from anti-PD-L1 therapies. While many PD-L1 assays are available, only the VENTANA platform with the anti-PD-L1 (SP142) antibody is licensed as a companion diagnostic device for selecting patients with metastatic/advanced TNBC who are candidates for treatment with atezolizumab. In this article, we provide a summary of an expert round-table discussion about PD-L1 testing, using the SP142 antibody in metastatic TNBCeng© 2021 Federico Rojo (on behalf of all co-authors). This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/AntibodyBreast cancerDiagnosisImmunohistochemistryImmunotherapyPD-L1journal article10.2217/fon-2020-11001744-8301open access